Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H22N4O3 |
| Molecular Weight | 318.3709 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1C2=C(NC(=N2)[C@H]3CCC(=O)C3)C(=O)N(CCC)C1=O
InChI
InChIKey=RUHGOZFOVBMWOO-JTQLQIEISA-N
InChI=1S/C16H22N4O3/c1-3-7-19-14-12(15(22)20(8-4-2)16(19)23)17-13(18-14)10-5-6-11(21)9-10/h10H,3-9H2,1-2H3,(H,17,18)/t10-/m0/s1
| Molecular Formula | C16H22N4O3 |
| Molecular Weight | 318.3709 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Apaxifylline is an adenosine A1 receptor antagonist that was under investigation with Boehringer Ingelheim as a potential neuroprotective drug for the treatment of dementia. Apaxifylline was able to antagonize scopolamine-induced deficits in the rat in a memory task. A single oral application of apaxifylline 90 min before the rats received the noxious stimulus significantly attenuated the scopolamine-induced deficits observed during the retention trial of the rat in the passive avoidance paradigm. Apaxifylline treatment does not influence motility.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:54:20 GMT 2023
by
admin
on
Fri Dec 15 15:54:20 GMT 2023
|
| Record UNII |
OG8HSX6N6H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1509
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
151581-23-6
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY | |||
|
60949
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY | |||
|
OG8HSX6N6H
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY | |||
|
SUB05536MIG
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY | |||
|
100000086976
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY | |||
|
C81046
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY | |||
|
7264
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY | |||
|
GG-37
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104538
Created by
admin on Fri Dec 15 15:54:20 GMT 2023 , Edited by admin on Fri Dec 15 15:54:20 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
